Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β <sub>2</sub> -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis-Reference-Cited by-同舟云学术

Comparative effectiveness and safety of inhaled corticosteroid plus long-acting β ₂ -agonist fixed-dose combinations vs. long-acting muscarinic antagonist in bronchiectasis

Published:2024-01-26 Issue:2 Volume:17 Page:157-164
ISSN:1751-2433
Container-title:Expert Review of Clinical Pharmacology
language:en
Short-container-title:Expert Review of Clinical Pharmacology

Author:

Su Vincent Yi-Fong¹²³,Ding Ting-Lin⁴⁵,Chang Yuh-Lih⁴⁵⁶^ORCID,Chou Yueh-Ching⁴⁵⁶^ORCID,Hwang Hsuen-En²⁷^ORCID,Chou Chian-Ying⁴⁵,Hsu Chia-Chen⁴⁵^ORCID

Affiliation:

1. Faculty of Medicine, School of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

2. Department of Internal Medicine, Taipei City Hospital, Taipei City Government, Taipei, Taiwan

3. Department of Exercise and Health Sciences, College of Kinesiology, University of Taipei, Taipei, Taiwan

4. Department of Pharmacy, Taipei Veterans General Hospital, Taipei, Taiwan

5. Department of Pharmacy, School of Pharmaceutical Sciences, National Yang Ming Chiao Tung University, Taipei, Taiwan

6. Institute of Pharmacology, College of Medicine, National Yang Ming Chiao Tung University, Taipei, Taiwan

7. Department of Radiology, Taipei Veterans General Hospital, Taipei, Taiwan

Funder

Taipei Veterans General Hospital

National Science and Technology Council

Publisher

Informa UK Limited

Link

https://www.tandfonline.com/doi/pdf/10.1080/17512433.2024.2306218

Reference33 articles.

1. Changes in the incidence, prevalence and mortality of bronchiectasis in the UK from 2004 to 2013: a population-based cohort study

2. Prevalence and incidence of bronchiectasis in Italy

3. Evaluating the Prevalence and Incidence of Bronchiectasis and Nontuberculous Mycobacteria in South Korea Using the Nationwide Population Data

4. Increasing bronchiectasis prevalence in Germany, 2009–2017: a population-based cohort study

5. Comorbidities and mortality risk factors for patients with bronchiectasis